Medtronic Archives - Page 4 of 59 - Medical Design Sourcing

How Medtronic’s using AI: Artificial intelligence insights and advice from the C-suite

Dr. Salomón Zebede prepares to operate using Medtronic’s Hugo robotic-assisted surgery system at Pacifica Salud Hospital in Panama. The hospital also uses Medtronic’s AI-powered Touch Surgery Enterprise product. [Photo courtesy of Medtronic]

Medtronic AI products are catching colon cancer, assisting surgeons and finding new uses across the varying technologies developed by the world’s largest medical device manufacturer.

In recent interviews, Medtronic executives discussed how artificial intelligence is leading to new or improved devices. They also offered insights that can help device designers and engineers across the medtech industry take advantage of the rapidly advancing technology.

“We’re harnessing the power of AI today for use in clinical decision support, creating new indications, and delivering personalized treatments,” Medtronic Chair and CEO Geoff Martha sa…

Medtronic brings back former VP as GM of Aortic unit

Simona Zannetti, GM of the Medtronic Aortic business unit. [Image from Simona Zannetti on LinkedIn]Medtronic (NYSE: MDT) + announced that it named Dr. Simona Zannetti as the GM of its Aortic business unit.

Zannetti previously spent 21 years at the medtech giant. She spent the last 16 months as SVP of clinical research at Penumbra, joining the interventional device maker in September 2022.

In a LinkedIn post today, Nina Goodheart, SVP and president, Structural Heart & Aortic at Medtronic, shared the news of Zannetti’s return.

“She is a familiar face to many of us and we’re so glad to have her back,” Goodheart wrote.

Among several roles at Medtronic over more than two decades, Zannetti most recently served as VP of clinical research and medical science for peripheral vascular health. She also had the post of VP of clinical research and the Office of Medical Affairs, Aortic, Peripheral and…

The biggest stories from the 2024 J.P. Morgan Healthcare Conference

Medtronic’s Geoff Martha, Dexcom’s Kevin Sayer and J&J’s Joaquin Duato spoke at this year’s J.P. Morgan Healthcare Conference.

Some of the biggest names in medtech came together this week at the J.P. Morgan Healthcare Conference. They shared updates on financial progress, operational changes and new products, among other things.

Medtronic shared details on plans to restore earnings power, while Abbott highlighted the success of its FreeStyle Libre system. Shockwave Medical outlined its plans for growth, while Dexom

Here are some of the biggest stories to come out of this year’s edition of the J.P. Morgan Healthcare Conference.

Medtronic focuses on earnings power while shifting operational setup

Medtronic Chair and CEO Geoff Martha’s presentation centered on profits for the medtech giant.

“Our top priority is restoring our earnings power — full stop,” he said. “We continue to be this mission-driven company th…

The most important medtech leadership changes of 2023

Former Johnson & Johnson EVP and MedTech Worldwide Chair Ashley McEvoy [Photo courtesy of Johnson & Johnson]

From hirings and firings to promotions, resignations and surprising shake-ups, these were the most important medtech leadership changes of the year.

By Associate Editor Sean Whooley and Managing Editor Jim Hammerand

The leadership change at Johnson & Johnson MedTech was a surprising shift that ended up as the year’s biggest medtech leadership change of 2023.

In October, J&J EVP and J&J MedTech Worldwide Chair Ashley McEvoy announced her resignation from the world’s second-largest device manufacturer. She’s staying on into the first quarter of 2024 while her successor, Tim Schmid, gets settled into his new role.

Schmid, a 30-year J&J vet who was most recently company group chair of J&J MedTech Asia Pacific, said he’s “committed to building ev…

Medtronic cuts suppliers and manufacturing sites, CEO says in supply chain and operations update

Medtronic CEO and Chair Geoff Martha [Photo courtesy of Medtronic]

Medtronic is closing at least five manufacturing sites, consolidating distribution centers and stopped doing business with approximately 200 suppliers as part of a push to improve its operations and supply chain.

That’s according to a presentation by Medtronic Chair and CEO Geoff Martha at the J.P. Morgan Healthcare Conference today emphasizing the focus on profitability at the world’s largest medical device manufacturer.

“One of the biggest opportunities for us to leverage our scale and drive leveraged earnings over time is with our global operations and supply chain,” Martha said. “We spent nearly $11 billion on cost of goods sold last year. That’s a lot. And over half of the company’s employees are involved in global operations and supply chain.”

Medtronic is “also beginning to wor…

Medtronic CEO: ‘Our top priority is restoring our earnings power — full stop.’

Medtronic Chair and CEO Geoff Martha [Photo courtesy of Medtronic]Medtronic (NYSE: MDT) + Chair and CEO Geoff Martha focused on the push for profits at the world’s largest medical device manufacturer in his presentation at the J.P. Morgan Healthcare Conference today.

“Our top priority is restoring our earnings power — full stop,” he said, citing Medtronic’s recent reorganizations and changes to incentives, product approvals and launches, and new initiatives like the Medtronic AI Center of Excellence.

“We continue to be this mission-driven company that you know Medtronic to be and our customers and patients know Medtronic to be, but at the same time, performance driven,” he said. “You’ve got to be both. It’s not one without the other: no margin, no mission.”

Martha also offered details of Medtronic’s efforts to leverage its buying power and improve ef…

Medtronic wins FDA nod for ‘game-changing’ DBS device

The Percept RC deep brain stimulation system [Image courtesy of Medtronic]Medtronic (NYSE: MDT) + today announced FDA approval of its Percept RC deep brain stimulation system, the latest member of its Percept line of DBS devices.

The medtech giant describes the Percept RC as the first DBS sensing-enable rechargeable device. In a presentation at the J.P. Morgan Healthcare Conference earlier today, CEO Geoff Martha called it a “game-changing” device that exemplifies “how Medtronic engineers are really leading the industry in innovation, developing smaller devices and inventing sensing technology to improve therapeutic benefit.”

Medtronic officials see Percept RC — and the company’s closed-loop rechargeable Inceptiv spinal cord stimulator — expanding share in what they describe as a combined $3.3 billion DBS and SCS sector.

The Medtronic Percept family already included the Percept PC neur…

Medtronic wins CE mark for MiniMed 780G with Simplera Sync disposable, all-in-one CGM

The MiniMed 780G with the Simplera Sync CGM and accompanying devices. [Image courtesy of Medtronic]Medtronic (NYSE: MDT) + announced today that it received CE mark approval for its MiniMed 780G system with Simplera Sync.

Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM), eliminates the need for fingersticks and overtape. It features an improved user experience at half the size of previous Medtronic sensors with a simple, two-step insertion process.

MiniMed 780G, an automated insulin delivery system, offers meal detection technology and provides automatic adjustments and corrections to sugar levels every five minutes. This occurs for both basal (background) and bolus (mealtime) insulin needs.

Get the full story at our sister site, Drug Delivery Business News.

Medtronic wins CE mark for next-gen Micra leadless pacemakers

The Micra AV2 and Micra VR2 leadless pacemakers. [Images courtesy of Medtronic]Medtronic (NYSE: MDT) + announced today that it received CE mark approval for its next-generation Micra AV2 and Micra VR2 miniature, leadless pacemakers.

CE mark follows FDA approval for both devices in May of last year.

The pacemakers — which Medtronic labels as the world’s smallest — provide longer battery life and easier programming than earlier versions. Micra AV2 and Micra VR2 offer approximately 40% more battery life than previous generations. Medtronic projects battery life of nearly 16 and 17 years, respectively, for the devices.

Still, they deliver the benefits of leadless pacing like reduced complications compared to traditional pacemakers, Medtronic says. According to a news release, more than 80% of patients who receive a Micra may only require one device for life.

Micra devices also offer remote monitoring capab…

AI basics from Medtronic Chief Technology and Innovation Officer Ken Washington

Medtronic SVP and Chief Technology and Innovation Officer Ken Washington [Photo courtesy of Medtronic]

Medtronic SVP and Chief Technology and Innovation Officer Ken Washington was recently briefing the 15 general managers who run each of the operating units at the world’s largest medical device manufacturer.

In the middle of the first chart in his presentation on artificial intelligence, one of the leaders stopped him.

As Washington tells it, they said, “I just don’t understand all these different buzzwords around AI. Can you tell me what are the different types of AI? How does it all work? And what’s the difference between generative AI and deep learning?”

Washington — who joined Medtronic in June 2023 after serving as VP and GM of consumer robotics at Amazon and CTO at Ford Motor Co. before that — pulled out an easel, grabbed a marker, and walked the group through t…

The 10 biggest diabetes tech stories from 2023

Medtronic, EOFlow, Dexcom, Beta Bionics and Tandem Diabetes Care all contributed some of the biggest diabetes technology stories of 2023.

It was another banner year for diabetes technology, with regulatory approvals, product launches and M&A all playing their part.

Diabetes technology’s impressive 12 months marked a major trend across medtech as a whole, too.

In 2022, the diabetes space saw plenty of progress from some of its biggest names and this past year proved no different. Big hitters like Dexcom, Abbott, Medtronic, Insulet and more all contributed to some of the biggest stories in 2023. External factors — like popular GLP-1 drugs and big tech names looking to enter the space — also made the cut.

Here are 10 of the most intriguing diabetes technology stories from the past 12 months.

Medtronic was set to buy EOFlow — until it wasn’t

The medtech giant made a big splash in the insulin delivery space when it announced its plan to buy South K…

The top medtech trends of 2023

The top medtech trends of 2023 included innovations such as artificial intelligence, new GLP-1 weight loss drugs and some long-awaited medtech finally receiving regulatory nods.

With health providers facing additional challenges on top of an ever-uncertain economic environment, medtech companies also made major readjustments: layoffs, spinoffs, reorganizations and much more.

Here are the top stories that caught the attention of MassDevice readers and editors in 2023.

Top 2023 medtech trend No. 10: Questions about GLP-1 drugs

U.S. health providers wrote more than 9 million prescriptions in just three months for Wegovy, Ozempic and similar glucagon-like peptide-1 (GLP-1) weight loss drugs, according to analytics firm Trilliant Health. The popularity and initial effectiveness of the new drugs had medtech industry analysts asking a lot of questions about how the potential health benefits could reduce demand for devices. Medical device executives, however, we…